# The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct03129490` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03129490](<https://clinicaltrials.gov/study/NCT03129490>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03129490

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 11000 participants.

## Technical summary

Registry record NCT03129490. Randomized; single masking; primary purpose prevention. Start 2023-04-01 (actual); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 11000 participants (planned count; ClinicalTrials.gov record NCT03129490, source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)
- Started: 2023-04-01 (actual) (ClinicalTrials.gov record NCT03129490, source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT03129490, source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)
- Completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT03129490, source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03129490, source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03129490-2025-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
- Acronym: DANNOAC-AF
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter
- Intervention (Drug): Dabigatran Etexilate Oral Capsule
- Intervention (Drug): Rivaroxaban Oral Tablet
- Intervention (Drug): Edoxaban Oral Tablet
- Intervention (Drug): Apixaban Oral Tablet
- Lead sponsor: Herlev and Gentofte Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)
- Registry lists this organization as the lead sponsor: Herlev and Gentofte Hospital (`cardio:org-herlev-and-gentofte-hospital`)

## Provenance

Content hash: 6cf242b8a6d493476597e91eeb32eaa14231f9254b2251adcff9df3a030bc3df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
